Danielle Cazabon

Danielle Cazabon

Auto-generated profile, based on publicly available information

Danielle Cazabon

Resolve To Save Lives, New York, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in BMC Public Health
Verified
Journal Article
Open access
PDF file
WAWichai Aekplakorn
Wichai Aekplakorn
SCSuwat Chariyalertsak
Suwat Chariyalertsak
PKPattapong Kessomboon
Pattapong Kessomboon
SASawitri Assanangkornchai
Sawitri Assanangkornchai
STSurasak Taneepanichskul
Surasak Taneepanichskul
OAObehioye Aimiosior
Obehioye Aimiosior
Background: Under Thailand’s universal health coverage every citizen has access to primary care including free hypertension treatment. This study describes temporal trends in hypertension prevalence, awareness, treatment, and control in Thailand. Methods: Data were analyzed from four survey cycles of Thailand’s National Health Examination Survey (NHES), between 2004 and 2019–2020. The NHES is a nationally-representative cross-sectional survey conducted every five years using a multistage probability sample. Hypertension was defined as systolic blood pressure > = 140 or diastolic blood pressure > = 90 mmHg or currently taking antihypertensive medicines; blood pressure control was defined as < 140/90 mmHg for patients without diabetes and < 130/80 mmHg for those with diabetes. Results: In 2019–2020, age-standardized hypertension prevalence in Thailand was 25.7% (24.6% females, 26.8% males). Among people with hypertension, 51.5% were aware of their diagnosis, 47.9% were treated, and 22.7% had controlled blood pressure. Age-standardized hypertension prevalence remained relatively unchanged in Thai adults from 2004 to 2019–2020, however trends varied by age group. Hypertension control increased from 8.8% in 2004 to a peak of 30% in 2014 but dropped to 22.7% by 2019–2020. Hypertension awareness increased from 30.7 to 55.8% between 2004 and 2014, but decreased to 51.5% by 2019–2020. Conclusion: Hypertension prevalence in Thailand has remained high over the past 15 years. Despite universal health coverage, hypertension awareness has not improved and blood pressure control has decreased in the past five years. An urgent and concerted public health response is needed to improve diagnosis and control of hypertension to prevent avoidable cardiovascular disease.

21 October 2022 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
SSSwagata Kumar Sahoo
Swagata Kumar Sahoo
APAnupam Khungar Pathni
Anupam Khungar Pathni
AKAshish Krishna
Ashish Krishna
BSBhawna Sharma
Bhawna Sharma
DCDanielle Cazabon
Danielle Cazabon
DHDagmara Hering
Dagmara Hering
Hypertension is a major public health challenge in low- and middle-income countries (LMICs) and calls for large-scale effective hypertension control programs. Adoption of drug and dose-specific treatment protocols recommended by the World Health Organization-HEARTS Initiative is key for hypertension control programs in LMICs. We estimated the annual medication cost per patient using three such protocols (protocol-1 and protocol-2 with Amlodipine, Telmisartan, using add-on doses and different drug orders, adding Chlorthalidone; protocol-3 with a single-pill combination (SPC) of Amlodipine/Telmisartan with dose up-titration, and addition of Chlorthalidone, if required) in India. The medication cost was simulated with different hypertension control assumptions for each protocol and calculated based on prices in the public and private sectors in India. The estimated annual medication cost per patient for protocol-1 and protocol-2 was $33.88–58.44 and $51.57–68.83 for protocol-3 in the private sector. The medication cost was lower in the generic stores ($5.78–9.57 for protocol-1 and protocol-2, and $7.35–9.89 for protocol-3). The medication cost for patients was the lowest ($2.05–3.89 for protocol-1 and protocol-2, and $2.94–3.98 for protocol-3) in the public sector. At less than $4 per patient per annum, scaling up a hypertension control program with specific treatment protocols is a potentially cost-effective public health intervention. Expanding low-cost generic retail networks would extend affordability in the private sector. The cost of treatment with SPC is comparable with non-SPC protocols and can be adopted in a public health program considering the advantage of simplified logistics, reduced pill burden, improved treatment adherence, and blood pressure control.

2 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
STSovannary Tuot
Sovannary Tuot
ATAlvin Kuo Jing Teo
Alvin Kuo Jing Teo
DCDanielle Cazabon
Danielle Cazabon
SSSay Sok
Say Sok
MUMengieng Ung
Mengieng Ung
Siyan YiSiyan Yi
Siyan Yi
With support of the national tuberculosis (TB) program, KHANA (a local non-governmental organization in Cambodia) has implemented an innovative approach using a seed-and-recruit model to actively find TB cases in the community. The model engaged community members including TB survivors as seed and newly diagnosed people with TB as recruiters to recruit presumptive TB cases in their social network in a snowball approach for screening and linkage to treatment. This study aimed to explore the acceptability of the active case finding with the seed-and-recruit model in detecting new TB cases and determine the characteristics of successful seeds. This qualitative study was conducted in four provinces (Banteay Meanchey, Kampong Chhnang, Siem Reap, and Takeo) in Cambodia in 2017. Fifty-six in-depth interviews and ten focus group discussions (with a total of 64 participants) were conducted with selected beneficiaries and key stakeholders at different levels to gain insights into the acceptability, strengths, and challenges in implementing the model and the characteristics of successful seeds. Transcripts were coded and content analyses were performed. The seed-and-recruit active case finding model was generally well-received by the study participants. They saw the benefits of engaging TB survivors and utilizing their social network to find new TB cases in the community. The social embeddedness of the model within the local community was one of the major strengths. The success of the model also hinges on the integration with existing health facilities. Having an extensive social network, being motivated, and having good knowledge about TB were important characteristics of successful seeds. Study participants reported challenges in motivating the presumptive TB cases for screening, logistic capacities, and high workload during the implementation. However, there was a general consensus that the model ought to be expanded. These findings indicate that the seed-and-recruit model is well-accepted by the beneficiaries and key stakeholders. Further studies are needed to more comprehensively evaluate the impacts and cost-effectiveness of the model for future expansion in Cambodia as well as in other resource-limited settings.

10 June 2021 in Global Heart
Verified
Journal Article
Open access
PDF file
SSSoraphan Songsermpong
Soraphan Songsermpong
SBSushera Bunluesin
Sushera Bunluesin
PKPanisara Khomgongsuwan
Panisara Khomgongsuwan
SJSupattra Junthon
Supattra Junthon
DCDanielle Cazabon
Danielle Cazabon
RGRenu Garg
Renu Garg
During the COVI9-19 pandemic, Pakkred hospital in Thailand implemented innovative practices to ensure the continuation of essential medical services for non-communicable disease patients. These practices included decentralized care, telemedicine, home blood pressure monitoring, community delivery of medicines, and facility infrastructure changes. Despite the decrease in hospital visits by hypertension patients during the pandemic, our results suggest that this package of interventions may have contributed to sustained hypertension and diabetes control rates in Pakkred district.

2 September 2021 in Global Heart
Verified
Journal Article
Open access
PDF file
RTRebecca L. Tisdale
Rebecca L. Tisdale
DCDanielle Cazabon
Danielle Cazabon
AMAndrew E. Moran
Andrew E. Moran
MRMiriam Rabkin
Miriam Rabkin
HBHelen Bygrave
Helen Bygrave
JCJennifer Cohn
Jennifer Cohn
Expanding hypertension services in low- and middle-income countries requires efficient and effective service delivery approaches that meet the needs and expectations of people living with hypertension within the resource constraints of existing national health systems. Ideally, a hypertension program will extend treatment coverage while maintaining service quality, maximizing efficient resource utilization and improving clinical outcomes. In this article, we discuss lessons learned from HIV differentiated service delivery initiatives, and make the case that the same approach should be adopted for hypertension programs.

2 September 2022 in Revista Panamericana de Salud Pública
Verified
Journal Article
Open access
PDF file
AMAndrew E. Moran
Andrew E. Moran
MFMargaret Farrell
Margaret Farrell
DCDanielle Cazabon
Danielle Cazabon
SSSwagata Kumar Sahoo
Swagata Kumar Sahoo
DMDoris Mugrditchian
Doris Mugrditchian
RGRenu Garg
Renu Garg
Generally, hypertension control programs are cost-effective, including in low- and middle-income countries, but country governments and civil society are not likely to support hypertension control programs unless value is demonstrated in terms of public health benefits, budget impact, and value-for-investment for the individual country context. The World Health Organization (WHO) and the Pan American Health Organization (PAHO) established a standard, simplified Global HEARTS approach to hypertension control, including preferred antihypertensive medicines and blood pressure measurement devices. The objective of this study is to report on health economic studies of HEARTS hypertension control package cost (especially medication costs), cost-effectiveness, and budget impact and describe mathematical models designed to translate hypertension control program data into the optimal approach to hypertension care service delivery and financing, especially in low- and middle-income countries. Early results suggest that HEARTS hypertension control interventions are either cost-saving or cost-effective, that the HEARTS package is affordable at between US$ 18-44 per person treated per year, and that antihypertensive medicines could be priced low enough to reach a global standard of an average <US$ 5 per patient per year in the public sector. This health economic evidence will make a compelling case for government ownership and financial support for national scale hypertension control programs.